Sortis 10 mg ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 93 | Primary biliary cholangitis | 1 |
93. Primary biliary cholangitis
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-002160-28-AT (EUCTR) | 23/09/2005 | 19/08/2005 | Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis | Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis | Reduction of cardiovascular risk may become key for the management of PBC. Therefore information on safety and efficacy (lipid-lowering effects) of statins in chronic cholestatic disorders is essential. Moreover, the study will answer the open question whether long-term treatment with statins may have potential beneficial effects on the course of PBC. | Trade Name: Sortis Product Name: Sortis 10 mg INN or Proposed INN: Atorvastatin | Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology | NULL | Not Recruiting | Female: yes Male: yes | 80 | Austria |